Therapeutic and diagnostic challenges for frontotemporal dementia
In the search for therapeutic modifiers, frontotemporal dementia (FTD) has traditionally been overshadowed by other conditions such as Alzheimer’s disease. A clinically and pathologically diverse condition, FTD has been galvanized by a number of recent discoveries such as novel genetic variants in...
Main Authors: | , |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2014-08-01
|
Series: | Frontiers in Aging Neuroscience |
Subjects: | |
Online Access: | http://journal.frontiersin.org/Journal/10.3389/fnagi.2014.00204/full |
id |
doaj-408fb388e9054b559f072a296abf83be |
---|---|
record_format |
Article |
spelling |
doaj-408fb388e9054b559f072a296abf83be2020-11-24T23:29:53ZengFrontiers Media S.A.Frontiers in Aging Neuroscience1663-43652014-08-01610.3389/fnagi.2014.00204103593Therapeutic and diagnostic challenges for frontotemporal dementiaSimon eD'Alton0Jada eLewis1University of FloridaUniversity of FloridaIn the search for therapeutic modifiers, frontotemporal dementia (FTD) has traditionally been overshadowed by other conditions such as Alzheimer’s disease. A clinically and pathologically diverse condition, FTD has been galvanized by a number of recent discoveries such as novel genetic variants in familial and sporadic forms of disease and the identification of TAR DNA binding protein of 43kDa (TDP-43) as the defining constituent of inclusions in more than half of cases. In combination with an ever-expanding knowledge of the function and dysfunction of tau - a protein which is pathologically aggregated in the majority of the remaining cases - there exists a greater understanding of FTD than ever before. These advances may indicate potential approaches for the development of hypothetical therapeutics, but FTD remains highly complex and the roles of tau and TDP-43 in neurodegeneration are still wholly unclear. Here the challenges facing potential therapeutic strategies are discussed, which include sufficiently accurate disease diagnosis and sophisticated technology to deliver effective therapies.http://journal.frontiersin.org/Journal/10.3389/fnagi.2014.00204/fullFrontotemporal DementiaFrontotemporal Lobar DegenerationTherapeuticstauTDP-43 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Simon eD'Alton Jada eLewis |
spellingShingle |
Simon eD'Alton Jada eLewis Therapeutic and diagnostic challenges for frontotemporal dementia Frontiers in Aging Neuroscience Frontotemporal Dementia Frontotemporal Lobar Degeneration Therapeutics tau TDP-43 |
author_facet |
Simon eD'Alton Jada eLewis |
author_sort |
Simon eD'Alton |
title |
Therapeutic and diagnostic challenges for frontotemporal dementia |
title_short |
Therapeutic and diagnostic challenges for frontotemporal dementia |
title_full |
Therapeutic and diagnostic challenges for frontotemporal dementia |
title_fullStr |
Therapeutic and diagnostic challenges for frontotemporal dementia |
title_full_unstemmed |
Therapeutic and diagnostic challenges for frontotemporal dementia |
title_sort |
therapeutic and diagnostic challenges for frontotemporal dementia |
publisher |
Frontiers Media S.A. |
series |
Frontiers in Aging Neuroscience |
issn |
1663-4365 |
publishDate |
2014-08-01 |
description |
In the search for therapeutic modifiers, frontotemporal dementia (FTD) has traditionally been overshadowed by other conditions such as Alzheimer’s disease. A clinically and pathologically diverse condition, FTD has been galvanized by a number of recent discoveries such as novel genetic variants in familial and sporadic forms of disease and the identification of TAR DNA binding protein of 43kDa (TDP-43) as the defining constituent of inclusions in more than half of cases. In combination with an ever-expanding knowledge of the function and dysfunction of tau - a protein which is pathologically aggregated in the majority of the remaining cases - there exists a greater understanding of FTD than ever before. These advances may indicate potential approaches for the development of hypothetical therapeutics, but FTD remains highly complex and the roles of tau and TDP-43 in neurodegeneration are still wholly unclear. Here the challenges facing potential therapeutic strategies are discussed, which include sufficiently accurate disease diagnosis and sophisticated technology to deliver effective therapies. |
topic |
Frontotemporal Dementia Frontotemporal Lobar Degeneration Therapeutics tau TDP-43 |
url |
http://journal.frontiersin.org/Journal/10.3389/fnagi.2014.00204/full |
work_keys_str_mv |
AT simonedalton therapeuticanddiagnosticchallengesforfrontotemporaldementia AT jadaelewis therapeuticanddiagnosticchallengesforfrontotemporaldementia |
_version_ |
1725543946235412480 |